ALIROCUMAB TITRATION STRATEGY ALLOWS INDIVIDUALIZED LDL-C REDUCTION IN A REAL WORLD SETTING: RESULTS FROM ODYSSEY OLE (LONG TERM COHORT)

Robert Dufour,G. Kees Hovingh,John Guyton,Gisle Langslet,Marie Baccara-Dinet, Chantal Din-Bell,Garen Manvelian,Michel Farnier

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

引用 0|浏览3

暂无评分

摘要

Background: Patients with heterozygous familial hypercholesterolemia (HeFH) who completed the 78-week LONG TERM study (LT) of alirocumab (ALI) were eligible to enroll in an open-label study (OLE; [NCT01954394][1]). In contrast to previous ODYSSEY studies (where ALI dose was increased automatically

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要